ICESP

ICE Pharma has over seven decades of experience as a global leader in the development and manufacture of bile acid derivatives. The company’s flagship product, ursodeoxycholic acid (UDCA), serves as an active pharmaceutical ingredient for liver disease therapies. They offer a broad portfolio including APIs, excipients, finished dosage forms, nutraceuticals focused on immune/gut health, research chemicals for academia/R&D use, and branded cosmetics. Their integrated manufacturing network spans Europe, Latin America, Asia and Oceania with customers in over 50 countries. Since acquisition by Advent International in 2019 they have expanded through further acquisitions.

Clinical results per se are not published as they mainly supply ingredients rather than develop proprietary therapeutics.